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Abstract
Background: Daptomycin is a rapidly bactericidal agent with broad coverage against Gram-positive organisms,
including Staphylococcus aureus, the most frequent cause of osteomyelitis. The objective of this study was to
describe the clinical outcome of patients with non-hardware associated osteomyelitis, and the safety profile of
daptomycin in the treatment of these infections.
Methods: All patients with osteomyelitis, excluding concurrent orthopedic foreign body infections, treated with
daptomycin and identified between 2007–2008 in a retrospective, multicenter, observational registry, were included.
Investigators assessed patient outcome (cured, improved, failed, non-evaluable) at the end of daptomycin therapy.
Patients with a successful outcome at the end of daptomycin therapy were reassessed in 2009. All patients were
included in the safety analysis; evaluable patients were included in the efficacy analysis. Data was assessed using
descriptive statistics. A Kaplan Meier analysis was used to assess time to clinical failure.
Results: Two-hundred and nine osteomyelitis patients successfully completed daptomycin therapy in 2007–2008,
71 of which (34%) had a follow-up visit in 2009 and had an evaluable clinical outcome. The median (min, max)
daptomycin dose and duration were 6 mg/kg (4, 10) and 42 days (1, 88), respectively. Of the 52 patients with a
documented pathogen, S. aureus was the most common (42%); primarily methicillin-resistant S. aureus. All patients
were included in the safety analysis; evaluable patients were included in the efficacy analysis. Clinical resolution was
reported in 94% (CI - 86.2%, 98.44%) of patients. A Kaplan Meier analysis of time to clinical failure showed that
approximately 85% (CI – 64%, 95%) of patients had a continued successful outcome at the time of re-evaluation.
Eighteen patients (25%) in the safety population experienced an adverse event; 13 patients (18%) had an adverse
event that was possibly-related to daptomycin treatment.
Conclusions: Daptomycin appears to be an effective therapeutic choice with an acceptable safety profile in the
management of osteomyelitis that does not involve hardware.
Background
Osteomyelitis continues to represent a difficult therapeutic
challenge. Management of osteomyelitis typically includes
a prolonged course of antimicrobial therapy in addition to
surgical intervention. Staphylococcus aureus is the most
frequent cause of osteomyelitis, accounting for >50% of
cases [1]. Recent data suggest that methicillin-resistant S.
aureus (MRSA) is becoming less susceptible to vanco-
mycin, and has been associated with clinical failures when
vancomycin is utilized [2-5]. Data from a large cohort of
outpatient treatment for S. aureus osteomyelitis showed
that vancomycin was associated with a 2.5 times higher
relative risk of recurrence compared to β-lactams [6].
Therefore, alternatives to vancomycin are necessary.
Daptomycin is rapidly bactericidal against Gram-positive
organisms, including methicillin-susceptible S. aureus
(MSSA), MRSA and coagulase-negative staphylococci. The
bactericidal activity of daptomycin is concentration-
dependent in vitro and since it is not dependent on cell
growth, it maintains activity against bacteria in biofilm or
stationary growth phase [7-9]. Daptomycin is not FDA-
approved for bone and joint infections [10]; however, ani-
mal and clinical data indicate daptomycin has activity. A
rabbit experimental model of osteomyelitis showed infec-
tion clearance of 90%, 67%, 33% and 13% for daptomycin
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25 mg/kg, 15 mg/kg, vancomycin, and untreated controls,
respectively. Daptomycin doses of 25 and 15 mg/kg in the
rabbit correspond to equivalent human exposures from 8
and 6 mg/kg [11]. Clinical outcomes for osteomyelitis
patients from a retrospective, observational, non-
comparative registry showed that doses> 4 mg/kg were
more effective than doses≤ 4 mg/kg (88% vs 65%,
P=0.013) [12].
The aims of this study were to describe the clinical
outcome of daptomycin-treated patients with non-
hardware-associated osteomyelitis, as well as describe
the safety profile of daptomycin using data collected
in a multicenter retrospective registry.
Methods
CubicinW Outcomes Registry and Experience (COREW) is a
multicenter, retrospective, observational database designed
to collect the demographics, clinical outcome, and safety of
patients treated with daptomycin. The methods used to
collect data have been previously published [13,14]. Investi-
gators entered sequentially treated patients who received
daptomycin at their institution. Patients were not excluded
for any underlying disease or clinical presentation. Data for
this study came from 54 separate institutions in the United
States between January 2007 and December 2008. The
study was approved by the investigational review board of
the study centres.
All patients with osteomyelitis, excluding concurrent
orthopedic foreign body infections, who successfully fin-
ished therapy with daptomycin were identified. To deter-
mine the persistence of clinical success, patients with a
successful outcome at the end of daptomycin therapy in
2007 through 2008 were reassessed in 2009 for any contact
with their physician or institution related to their osteo-
myelitis treatment. Patients that had a follow-up visit in
2009 were considered eligible for inclusion in this study.
Efficacy of daptomycin at the end of therapy and at
follow-up was determined on the basis of the clinical re-
sponse of the patient as determined by the investigator
using a standardized definition. These definitions were
designed to be applicable to a wide range of infectious
processes and all qualifiers may not have been used for
the osteomyelitis patients in this study. Clinical response
was defined as resolved (any of the following: clinical
signs and symptoms are resolved and/or no additional
antibiotic therapy judged necessary, or infection cleared
with a negative culture result reported at the end of
therapy); improved (partial resolution of clinical signs
and symptoms or additional antibiotic therapy was ne-
cessary at the end of therapy not related to a worsening
infection); failed (any of the following: inadequate re-
sponse to therapy; resistant pathogen, worsening, or new
or recurrent signs and symptoms; need for a change in
antibiotic therapy; or a positive culture result reported at
the end of therapy); or non-evaluable (unable to deter-
mine response at the end of therapy because the record
did not contain adequate information). Follow-up visits
were left to the discretion of the treating physician and
patient compliance. Data was assessed using descriptive
statistics. A Kaplan Meier analysis was used to assess
time to clinical failure and survival estimates with the
lower and upper 95% confidence intervals are presented.
Estimation of 95% confidence intervals for proportions
was made by the exact binomial method.
The safety of daptomycin was determined on the basis
of the patient’s adverse events as reported by the investi-
gator. All patients data were reviewed for adverse events
during daptomycin and up to 30 days after completing
therapy. The causal relationship between daptomycin
treatment and the adverse event was described by the in-
vestigator as either not related (an adverse event with a
temporal relationship to the drug administered that
makes a causal relationship improbable, and/or for which
other drugs or underlying or concurrent disease provide a
plausible explanation) or possibly-related (a plausible tem-
poral relationship to the drug administered, but for which
other causative factor(s) could account for the event and
where improvements on dechallenge or dose reduction
may or may not have been observed).
Evaluable patients were included in the efficacy ana-
lysis. All patients were included in the safety analysis.
Results
There were 209 patients with non-hardware-associated
osteomyelitis that successfully completed daptomycin
therapy during the study period. Seventy-three patients
(36%) had follow-up information available and 71
patients had an evaluable clinical outcome. When data
on follow-up assessments were collected, at least one
year had passed since completion of daptomycin ther-
apy. During that period of time, the median time of as-
sessment was 35 days (min 1, max 798); 15 patients had
assessments at ≥ 6 months (all resolved) and 5 had
assessments at ≥ 1 year (all resolved). The failures oc-
curred at 5, 38, 62 and 147 days after daptomycin ther-
apy. Two non-evaluable patients were excluded from the
efficacy analysis but were included in the safety analysis.
The patient demographics are shown in Table 1. Overall,
the median daptomycin dose (min, max) was 6 mg/kg
(4, 10) and the median duration of therapy was 42 days (1,
88). Twenty-four (34%) patients received less than 6 mg/
kg and 47 (66%) patients received 6 or more mg/kg. The
diagnosis of osteomyelitis was established or confirmed by
the presence of the following: clinical signs and symptoms
(n= 65), MRI (n= 40), bone scan (n= 7), plain radiography
(n= 6), CT scan (n= 3), and cultures (primarily bone cul-
tures; n = 29). The duration of osteomyelitis was not col-
lected. Forty-five patients (63%) underwent a surgical
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intervention; including debridement (bone and tissue 16/71;
23% and tissue only 8/71; 11%). An additional 16 patients
(23%) underwent incision and drainage.
Seventy Gram-positive pathogens were isolated in 52
patients (73%), primarily from deep tissue and bone cul-
tures. Staphylococcus aureus was the most common
pathogen (30/71; 42%), primarily MRSA (19/30; 63%). The
other pathogens were coagulase-negative staphylococci
(13/71; 18%), Enterococcus spp. (7/71; 10%), and Strepto-
coccus spp. (3/71; 4%). Two patients had a Gram-negative
or unidentified pathogen and the remainder reported
negative cultures (n= 11) or no pathogen results (n= 6).
The use of concomitant antibiotics was documented in
43/71 patients (61%), primarily for Gram-negative and/
or anaerobic coverage. The most common concomitant
antibiotics were cephalosporins (15/43, 35%), carbape-
nems (11/43, 26%), and fluoroquinolones (11/43, 26%).
Antibiotics were used after daptomycin in 31 patients
(44%). Antimicrobials most commonly used included
doxycycline (n = 8), linezolid (n = 6), and trimethoprim-
sulfamethoxazole (n = 6). The median (min, max) dur-
ation of follow-up antibiotics was 29 days (4, 180).
Clinical resolution (resolved or improved) was reported
in 94% (CI - 86.2%, 98.44%) of patients. The criteria used
for outcome assessment included signs and symptoms
(n=67); laboratory tests such as white blood cell count,
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP) (n=19); radiologic tests (n= 12); and blood
(n=6) or other cultures (n=3). A Kaplan Meier analysis
was used to analyze time to clinical failure both overall and
stratified by dose (Figure 1 and 2). The analysis of time to
clinical failure showed that approximately 85% (CI – 64%,
95%) of patients had a continued successful outcome at the
time of re-evaluation. The analysis of time to clinical failure
showed that approximately 76% (CI – 31%, 94%) for less
than 6 mg/kg and 91% (CI – 65%, 98%) for greater than
equal to 6 mg/kg.
A subgroup analysis of 63 patients with confirmed osteo-
myelitis (radiologic evidence and/or bone culture), 52
patients with Gram-positive pathogens and 28 patients re-
ceiving daptomycin monotherapy showed success rates of
94% (CI - 85%, 98%), 96% (CI - 87%, 99%), and 96% (CI -
82%, 99%), respectively. The 18 patients meeting all 3 of
these characteristics had a success rate similar to the entire
cohort, 94% (CI - 73%, 99%). Additional details are provided
as these patients outcomes may be more directly related to
treatment with daptomycin. A review of their characteris-
tics only found a higher rate of chronic renal failure (n=4,
22%) in this group. Nine patients (50%) in this group had
switched to daptomycin due to a clinical failure of prior
therapy which was numerically higher than in the remain-
der of the cohort (12/53, 23%). There were 6 (33%) patients
who received antibiotic therapy after daptomycin: cefazolin,
trimethoprim/sulfamethoxazole, doxycycline (n=3) and
Table 1 Patient Demographics in Evaluable Population





≤ 50 20 (28)
51-65 24 (33)
≥ 66 27 (38)


















Multiple osteomyelitis sites 6 (8)
Concomitant infections
Skin and skin structure infection† 9 (13)
Bacteremia 5 (7)
Deep surgical site infection 5 (7)
Urinary tract infection/pyelonephritis 3 (4)
Septic arthritis 1 (1)
Underlying diseases*
Hypertension 34 (48)
Diabetes mellitus 31 (44)
Other cardiovascular disease 10 (14)
Peripheral vascular disease 13 (18)
Anemia/All hematologic diseases 10 (14)
Cardiac Arrhythmias 10 (14)
ICU stay during daptomycin 6 (9)
Initial CrCl< 30 ml/min 3 (4)
On dialysis 0 (0)
Data expressed as n (%) unless otherwise indicated.
† Types: major abscess n = 4, ulcer n = 2, wound n= 2, uncomplicated n = 1.
* Patients may have more than one underlying disease.
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vancomycin. The one failure in this group occurred in a pa-
tient who received doxycycline for suppressive therapy of
MRSA after daptomycin 6 mg/kg was administered for
70 days.
Thirty-six adverse events were reported in 18 (25%)
patients. Seventeen adverse events possibly related to dap-
tomycin occurred in 13 (18%) patients (Table 2). Creatine
phosphokinase (CPK) values were determined at baseline
in 29 (40%) patients and during daptomycin therapy in 63
(89%) patients, primarily weekly. One patient each had a
peak CPK value >5 to 10 times and >10 times the upper
limit of normal, both resolved while on daptomycin ther-
apy. Three (4%) patients discontinued daptomycin treat-
ment as a result of an adverse event. All adverse events
were mild to moderate in intensity.
Discussion
There is limited data on the outcomes of patients with
bone and joint infections that were treated with dapto-
mycin. Recent data indicates that vancomycin activity
against MRSA has decreased [4]. The current study of
patients with osteomyelitis was designed to collect out-
come data on patients treated with daptomycin, an alter-
native to vancomycin.
There are several limitations inherent to the retrospective
nature of this study, including the potential for patient se-
lection bias. However, the demographics of these patients
are similar to previously published studies with predomin-
antly older patients, with almost 50% with diabetes mellitus
and peripheral vascular disease [6]. Although the study was
conducted at a time when all previously treated patients
would have completed at least one year of follow-up assess-
ment, approximately two-thirds of the daptomycin treated
patients could not be included in this analysis due to a lack
of an outcome assessment. It is difficult to assess how a
higher rate of follow-up would have influenced the results.
This study collected outcomes based on the standard of
care practiced at each institution, as such; diagnostic proce-
dures, daptomycin dose and duration, and surgical inter-
ventions were uncontrolled.
Clinical resolution was documented at the follow-up as-
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Figure 2 Kaplan Meier Analysis, Time to Clinical Failure.
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approximately 85% of patients in a Kaplan Meier analysis
did not have recurrence of their infection. However, our
data should be considered in the context of the small sam-
ple size and the amount of censored data in the study.
These results are similar to previous studies. Finney et al.
evaluated daptomycin in a non-comparative study of early
clinical experience with bone and joint infections. Seven
osteomyelitis patients were treated with daptomycin at
doses ranging from 4 to 6 mg/kg, for a duration of therapy
between 8 to 42 days. Six of 7 patients had MRSA. The dur-
ation of follow-up was not reported. All patients had a suc-
cessful resolution of signs and symptoms [15]. Antony and
colleagues reported on their clinical experience with dapto-
mycin for the treatment of patients with Gram-positive
orthopedic infections. Of the 31 patients treated, 16 were
diagnosed with osteomyelitis; 14 of those had MRSA. Most
patients (77%) were treated with daptomycin at a dose of
6 mg/kg; the remainder received 4 mg/kg. The overall
cure rate was 87% and 100% for the 16 patients with osteo-
myelitis after 4 to 6 months of follow-up [16]. Shipton et al.
reported a case series of 7 patients with osteomyelitis
treated with daptomycin at a dose of 4 or 6 mg/kg for a
duration between 11 days to 8 weeks. Treatment was suc-
cessful in 3 (43%) cases after completing daptomycin and
follow-up of a mean of 7.3 months (range, 6–9 months).
Daptomycin in vitro non-susceptibility was reported in 1
patient [17]. A recent retrospective study by Licitra et al.
investigated the outcome of osteomyelitis or prosthetic joint
infections (PJI) patients after treatment with daptomycin at
a dose of ≥6 mg/kg for at least 2 weeks, (median 49 days;
range, 21–183). All patients had a Gram-positive pathogen.
Fifty-five of 59 (93%) osteomyelitis patients and 14/14
(100%) PJI patients were clinically cured or improved at
6 months after completing daptomycin [18].
This current study did not find that the outcomes of
patients with osteomyelitis and treated with daptomycin was
affected by the dose of <6 mg/kg compared to ≥6 mg/kg.
There is scant data in the literature to determine the optimal
daptomycin dose in osteomyelitis. An earlier study of a dif-
ferent cohort in the CORE registry of osteomyelitis patients
reported a successful outcome in 82% of patients after a me-
dian follow-up of 9 weeks. Clinical success was more com-
mon at a daptomycin dose >4 mg/kg than at dosages
≤4 mg/kg (88% vs. 65%; p=0.013) [12]. Rao et al. reported
that daptomycin administered at a dose of 4 mg/kg in 12
patients with PJI had a success rate of 50% (defined as no
clinical or radiographic recurrence; continued decline in ESR
and CRP levels; and continued improvement of joint func-
tion) after follow-up of 8 to 13 months. Most of the reported
failures retained hardware. This fact and the lower dose of
daptomycin used in this cohort may have contributed to the
low success rate [19]. As demonstrated, several studies have
shown a favourable clinical outcome and safety profile in
patients with osteomyelitis and PJI that were treated with
daptomycin [12,15,16,20,21]; however, failures including the
development of resistance have been reported [19,22,23].
The safety profile of daptomycin in this study com-
pares favorably to previous reports. The discontinuation
rate of 4% is similar to that reported in several studies of
osteomyelitis; 4% (3/73) by Licitra et al., 3% (1/31) by
Antony et al., 0% (0/12) by Rao et al., and 0% (0/36) by
Hernandez et al. [16,18,19,24]. The rate of CPK eleva-
tions was 11% (8/73); however, none discontinued and
only one patient had their daptomycin dose reduced.
This rate is somewhat higher than reported in the litera-
ture, which has ranged from 0% in smaller case series to
8% [16,18,19,24]. This variability may have been the re-
sult of several factors. Not all investigations have used
the same frequency of testing for CPK, ranging from
weekly examinations as recommended in the daptomy-
cin prescribing information to no routine testing of CPK
values. Furthermore, the cut-off values of significant
CPK elevation were variable.
Conclusions
In conclusion, daptomycin appears to be an effective
therapeutic choice for patients with osteomyelitis and
has an acceptable safety profile. Further studies looking
at the optimal dosage of daptomycin for patients with
osteomyelitis are warranted.
Table 2 Possibly-Related Adverse Events in the Safety
Population
Adverse Event N (%) Serious Action Taken Resolution







Yes Dose Reduced Resolved





Rash 2 (3) No Stopped
Permanently
Resolved
Chills 1 (1) No Stopped
Permanently
Resolved
Nausea 1 (1) No None Resolved
Photosensitivity Reaction 1 (1) No Stopped
Temporarily
Resolved
Pyrexia 1 (1) No Stopped
Permanently
Resolved
Subjects may have had more than one possibly related AE.
All adverse events were reported by the investigator.
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